Medicalgorithmics S.A. — Regulatory Filings 2023

Aug 25, 2023

Subject:Medicalgorithmics subsidiary Kardiolytics' receives two new Europeanpatents for computerized segmentation of contrast-filled coronaryvessels using computed tomography imaging and a medical imaging systemand method supported by technology for coronary segmentation

Currentreport no.:22/2023

Dateof preparation:August 24, 2023.

Legalbasis:Article 17 par. 1 of the MAR Regulation - confidential information.

TheManagement Board of Medicalgorithmics S.A. headquartered in Warsaw(_quot;Company_quot;) informs about the publication on August 23, 2023 for itssubsidiary, Kardiolytics Inc. (_quot;Cardiolytics_quot;), two European patentswith the following numbers: EP 3 726 460 B1 and EP 3719 744 B1. TheCompany received today (August 24, 2023) a notification of the patents'publication. Patent protection is granted after completing additionalformalities, in particular validating patents.

Thepatent EP3726460 involves a method for autonomously segmentingcontrast-filled coronary artery vessels in computed tomography (CT)images. This technology focuses on automating the process of identifyingand delineating coronary artery vessels that have been enhanced withcontrast material. This innovation could improve the efficiency andaccuracy of identifying coronary artery structures in medical imaging,potentially aiding in the diagnosis and treatment of cardiovascularconditions.

Thepatent EP3719744 presents a method and system that employ machinelearning for segmenting contrast-filled coronary artery vessels inmedical images. This technology focuses on using advanced algorithms toautomatically identify and delineate coronary artery structures thathave been enhanced with contrast material. This innovation aims toenhance the accuracy and efficiency of identifying coronary arteries inmedical imaging, potentially assisting in the diagnosis and managementof cardiovascular conditions._#160;

Theseare further patents obtained by Kardiolytics. Securing innovation andtechnology patents will enable Kardiolytics to promote and commercializeits inventions, including technology supporting computerized coronaryartery diagnostics. Most importantly, it will help protect Kardiolytics'unique intellectual property, enabling further development of thesolution and improving CAD (Coronary Artery Disease) diagnostics.

Kardiolytics,a company that develops solutions for medicine based on artificialintelligence, joined the Medicalgorithmics Group in November 2022.

TheIssuer publishes this information as it illustrates the development oftechnology for computer-assisted diagnosis and treatment of coronaryartery disease by Kardiolytics Inc.